WO2014030763A1 - 抗腫瘍剤 - Google Patents
抗腫瘍剤 Download PDFInfo
- Publication number
- WO2014030763A1 WO2014030763A1 PCT/JP2013/072686 JP2013072686W WO2014030763A1 WO 2014030763 A1 WO2014030763 A1 WO 2014030763A1 JP 2013072686 W JP2013072686 W JP 2013072686W WO 2014030763 A1 WO2014030763 A1 WO 2014030763A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cellobiose
- tumor
- day
- group
- test
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 25
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 claims abstract description 49
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 235000013305 food Nutrition 0.000 claims description 5
- 230000000259 anti-tumor effect Effects 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 12
- 206010028980 Neoplasm Diseases 0.000 description 50
- 238000012360 testing method Methods 0.000 description 37
- 239000000126 substance Substances 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 33
- 241001465754 Metazoa Species 0.000 description 31
- 238000000034 method Methods 0.000 description 21
- 201000011510 cancer Diseases 0.000 description 11
- 239000003183 carcinogenic agent Substances 0.000 description 11
- ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 10
- 108010059892 Cellulase Proteins 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 231100000357 carcinogen Toxicity 0.000 description 9
- 229940106157 cellulase Drugs 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 230000007704 transition Effects 0.000 description 9
- VFZRZRDOXPRTSC-UHFFFAOYSA-N DMBA Natural products COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 8
- 230000022534 cell killing Effects 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 230000005748 tumor development Effects 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 230000000711 cancerogenic effect Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 238000009395 breeding Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229920000742 Cotton Polymers 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 201000004384 Alopecia Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 238000010162 Tukey test Methods 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000235 effect on cancer Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 208000024963 hair loss Diseases 0.000 description 3
- 230000003676 hair loss Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000005336 safety glass Substances 0.000 description 3
- 239000008159 sesame oil Substances 0.000 description 3
- 235000011803 sesame oil Nutrition 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- WURBVZBTWMNKQT-UHFFFAOYSA-N 1-(4-chlorophenoxy)-3,3-dimethyl-1-(1,2,4-triazol-1-yl)butan-2-one Chemical compound C1=NC=NN1C(C(=O)C(C)(C)C)OC1=CC=C(Cl)C=C1 WURBVZBTWMNKQT-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000002737 cell proliferation kit Methods 0.000 description 2
- FYGDTMLNYKFZSV-ZWSAEMDYSA-N cellotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-ZWSAEMDYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000007515 enzymatic degradation Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 229920002749 Bacterial cellulose Polymers 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 101000957724 Catostomus commersonii Corticoliberin-1 Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010016275 Fear Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 240000000797 Hibiscus cannabinus Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 240000001462 Pleurotus ostreatus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 239000005016 bacterial cellulose Substances 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000013043 cell viability test Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- -1 etc. Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000002906 medical waste Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 239000013630 prepared media Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/24—Cellulose or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/04—Disaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to an antitumor agent.
- Patent Document 1 discloses an antitumor agent comprising an acidic xylo-oligosaccharide having a uronic acid residue in a xylo-oligosaccharide molecule and a Hatake shimeji extract as active ingredients. Further, (Patent Document 2) discloses an antitumor substance composed of a sugar ester of a monosaccharide or disaccharide and a fatty acid. These antitumor agents have insufficient antitumor effects and still have room for improvement.
- Patent Document 3 discloses an intestinal bacterial activator containing cellooligosaccharide such as cellobiose as an active ingredient. According to the present invention, cellooligosaccharides can selectively increase useful bacteria in the intestine and suppress the increase of harmful bacteria. However, the antitumor activity of cellooligosaccharides such as cellobiose has never been studied.
- Patent Document 4 discloses a cell killing action of a pharmaceutical containing cellobiose on cancer cells.
- Patent Document 4 uses cellobiose impurities that are extracts from plants, and this is also based on NMR data described in (Patent Document 4). it is obvious.
- the extract has a cell-killing effect. This also indicates that the extract is an impurity of cellobiose. I understand that.
- JP 2008-208093 A Japanese Patent Laid-Open No. 2002-179577 JP 2007-330177 A International Publication No. 2011/110190
- an object of the present invention is to provide an antitumor agent having excellent antitumor activity, high safety, and few side effects.
- the present inventors conducted extensive research and found that cellobiose, which is a type of oligosaccharide, suppresses the occurrence of cancer induced by carcinogens and completed the present invention. . That is, the gist of the present invention is as follows.
- An antitumor agent comprising cellobiose as an active ingredient.
- a pharmaceutical comprising the antitumor agent according to (1) above.
- a food containing the antitumor agent according to (1) above.
- an antitumor agent having excellent antitumor activity and high safety, and a drug and a food using the same can be obtained.
- the antitumor agent according to the present invention is characterized by containing cellobiose as an active ingredient.
- Cellobiose is a disaccharide in which two glucose molecules are connected by ⁇ 1, 4 bonds, and the chemical formula is C 12 H 22 O 11 .
- Such cellobiose can be appropriately produced by a method of decomposing a cellulosic substance with cellulase, a method of condensing or transferring a glucose sugar monosaccharide or a derivative thereof, a method of synthesizing from sucrose, and the like.
- both plant and animal substances are applicable.
- fibrous materials derived from natural products contained in cotton, wood, bamboo, kenaf, wheat, rice, bacterial cellulose, etc., regenerated cellulose obtained by dissolving them once in a solvent, or their chemistry The thing etc. which processed and made the cellulose derivative can be used. Any one of these cellulose materials may be used, or two or more of them may be used in combination.
- natural cellulosic materials that do not undergo dissolution or chemical treatment are preferred because the cellobiose obtained does not contain solvents or chemicals that are harmful to the human body.
- Any cellulase may be used as long as it has a decomposition activity on cellulose.
- the cellulase enzyme source include cellulase-producing bacterial cells themselves, those obtained by purifying enzymes secreted by cellulase-producing bacteria, and those obtained by formulating purified enzymes together with additives such as excipients and stabilizers.
- the dosage form may be any of powder, a granule, a liquid, etc.
- Examples of the enzymatic decomposition method using cellulase include a method in which a cellulosic substance is suspended in an aqueous medium, cellulase is added to the suspension, and the saccharification reaction is performed by heating while stirring or shaking. Can be mentioned.
- the suspension method, the stirring method, the addition method and order of addition of the cellulosic substance and cellulase, and the reaction conditions such as the concentration thereof can be appropriately set from the viewpoint of the yield of cellobiose.
- the conditions such as pH and temperature of the reaction solution may be any conditions so long as the cellulase is not inactivated. Specifically, when the reaction is performed at normal pressure, the temperature is 5 to 95 ° C. and the pH is 1 to 11. It can be a range.
- the cellobiose in the present invention can be obtained by enzymatic degradation of cotton (absorbent cotton).
- This method is advantageous in that the process time is extremely short compared to a method using woody materials as a raw material.
- the product obtained by enzymatic degradation of cotton has been confirmed by HPLC measurement to contain approximately 75% cellobiose, 22% glucose, and 3% cellotriose.
- the produced cellobiose can be subjected to purification treatment such as enzyme removal, desalting, and decolorization as necessary.
- purification treatment such as enzyme removal, desalting, and decolorization as necessary.
- a known method can be used without particular limitation.
- filtration treatment such as chromatography, microfiltration, ultrafiltration, and reverse osmosis membrane filtration, crystallization treatment, treatment with an ion exchange resin.
- Activated carbon treatment, and the like, and any of these treatments can be performed alone or in combination with a plurality of treatments.
- the cellobiose obtained as described above has antitumor activity for suppressing tumor development or tumor growth against various cancers such as breast cancer, and can be used as a medicine.
- a cellobiose antitumor agent is used as a pharmaceutical, its form is not particularly limited, and depending on the administration method and the conditions such as the type, shape and location of the applied tumor, tablets, capsules, powders, granules It can be appropriately selected from various forms such as an agent and a drink. That is, the anti-tumor agent of cellobiose can be used as a pharmaceutical as it is, or it may be combined with a usual additive such as a carrier, a diluent or an excipient as necessary.
- the ingestion or dosage of the antitumor agent according to the present invention is a therapeutically effective amount and cannot be generally specified depending on the type of tumor or the like, but in the case of an adult with a body weight of 60 kg, the amount of cellobiose per day is usually 240 mg or more. , Preferably 2400 mg or more.
- the upper limit of the dose is not particularly limited, but is preferably less than 4800 mg.
- the antitumor agent of the present invention can be used in combination with known antitumor agents or other therapeutic agents.
- the cellobiose antitumor agent according to the present invention can be contained in food in general and used as a functional food having antitumor activity.
- Cellobiose may be encapsulated using gelatin or the like, and the capsule may be used as a supplement food, or may be blended in beverages, confectionery, gum, candy and the like.
- Example 1 Purpose of study The antitumor effect of cellobiose was examined using a rat DMBA-induced breast cancer model.
- Test materials and equipment (1) Test substances and media a) Test substances Name: Cellobiose Properties: Powder Storage conditions: Low-temperature storage Handling precautions: Since it is highly hygroscopic, it was sealed after use and careful of moisture.
- DMBA 7,12-Dimethylbenzo [a] anthracene Storage conditions: Room temperature Manufacturer: SIGMA Handling precautions: To avoid inhalation and skin contact, a mask, safety glasses and gloves were worn.
- Sesame oil Storage conditions Room temperature Manufacturer: SIGMA Handling precautions: None in particular.
- Test method (1) Grouping Based on the following group composition table (Table 1) by stratified randomization method using animals with no abnormalities observed in general condition observation during quarantine / acclimation period, using body weight as an index Grouping was performed. Residual animals were excluded from the test group on the day of grouping, euthanized by ether excess anesthesia, and disposed.
- Monitoring animal setting In order to monitor the rearing environment, select the three animals with no abnormalities in the quarantine / acclimation period from the remaining animals after grouping in order of increasing individual identification number. Monitoring animals were set up. Monitoring animals were housed in the same animal room as the test group until the last autopsy day of the test group.
- a carcinogen was administered to each animal after grouping. That is, forcible oral administration was performed at a dose of 1 mL / animal using an oral sonde (disposable oral sonde, Fuchigami Instruments) and syringe (disposable syringe, Terumo Corp.). At the time of administration, a mask, safety glasses and gloves were worn to avoid inhalation and skin contact.
- test substance administration liquid For the preparation of the medium, CMC was weighed in the required amount using an electronic pan balance Sartorius Laboratory (Sartorius Co., Ltd.). The weighed CMC was added little by little while stirring distilled water in a beaker using a mighty magnetic stirrer (Koike Seimitsu Seisakusho). It moved to the graduated cylinder and made up to 0.5% (W / V). The prepared medium was stored and used under refrigeration for up to 9 days including the preparation date.
- test substance was weighed using an electronic analytical balance Sartorius Analytical (Sartorius Co., Ltd.).
- the weighed test substance was dissolved in a medium, transferred to a graduated cylinder and made up to a concentration of 0.8 and 8.0 mg / mL. It was prepared at the time of use.
- the remaining test substance administration solution after administration was diluted with a large amount of tap water and discarded.
- test substance Administration was started from the day after the grouping date (the first day). It was administered by oral gavage once a day for 12 consecutive weeks. At the time of administration, gavage was performed by oral gavage at 5 mL / kg / day according to the group composition table using an oral sonde (disposable oral sonde, Fuchigami Instruments) and syringe (disposable syringe, Terumo Corp.). The amount of liquid to be administered was calculated from the body weight value measured on the closest day at the time of administration.
- Fecal collection Feces were collected on the end of the administration period. In the morning of the harvest day, animals were transferred from the double cage to the breeding cage. After standing for 1 hour, feces excreted in the breeding cage were collected for each animal and stored in a deep freezer set at ⁇ 80 ° C.
- Dissection Anatomy was performed on the day after the end of the administration period.
- the laparotomy was performed under anesthesia with ether, and the blood was exsanguinated from the abdominal aorta. Thereafter, all the tumors of each individual were excised, and the wet weight was measured using an electronic balance TX323L (Shimadzu Corporation). Tumors after wet weight measurement were discarded.
- Test result (1) General state and weight transition The weight transition of each group is shown in FIG. The control group increased throughout the study period. The low-dose group and the high-dose group showed almost the same transition as the control group. There was no significant difference between the groups. As for the general condition, one animal died on the 8th day in the control group (animal number: 007). One animal died on day 4 in the low-dose group (animal number: 106). One animal died on day 76 in the high-dose group (animal number: 209).
- Tumor wet weight The tumor wet weight of each group is shown in FIG.
- the low dose group had approximately the same wet weight as the control group.
- the high dose group was not significant compared to the control group, but showed a lower value.
- Test material (1) Test substance Name: Cellobiose Storage method: Refrigerated, dark, dehumidified (2) Cells used Cell types: HeLa (human cervical cancer-derived cell line), HaCaT (human-derived immortalized keratinocytes) and Hep -G2 (human liver cancer-derived cell line) (3) Medium used Medium name: HeLa dedicated medium, HaCaT dedicated medium and Hep-G2 dedicated medium (4) Used reagent (for XTT assay) Reagent name: Cell Proliferation Kit (XTT) Manufacturer name: Cosmo Bio Co., Ltd. Catalog No. : 20-300-1000
- Test method cell thawing / passaging
- HeLa, HaCaT and Hep-G2 were thawed and cultured in various dedicated media.
- Cell passage was performed 2-3 times.
- Cells that recovered their proliferation were used for the test.
- HeLa, HaCaT, and Hep-G2 were seeded in 24 wells at 1 ⁇ 10 4 cells / 100 ⁇ L / well in each of two 96-well plates.
- the cells were cultured for 24 hours in a CO 2 incubator.
- the cells were cultured in a CO 2 incubator for 3 hours.
- the cells were photographed.
- the medium containing the test substance in one 96-well plate in which various cells were cultured was removed and replaced with a normal medium.
- Test Results The results of the XTT assay for HeLa, HaCaT and Hep-G2 are shown in FIGS. As is apparent from FIGS. 8 to 10, the survival rate of HeLa and HaCaT was almost unchanged compared to the control even at the test substance concentration of 10 mg / mL. In addition, in Hep-G2, a maximum decrease in survival rate of about 15% was observed in the high concentration group of the test substance. Further, as a confirmation of the performance of the kit used, the assay was performed using HeLa and dexamethasone which is an apoptosis inducer. The result is shown in FIG. A decrease in survival rate of about 40% was observed at 500 ⁇ M dexamethasone, confirming that there was no problem with the kit performance.
- FIGS. 8 to 10 show that high-purity cellobiose, which is the target substance of the present invention, does not have a cell-killing effect on cancer cells.
- FIGURE 9 of (Patent Document 4) shows that the compound has a cell-killing effect on cancer cells. From this, it was found that the compound described in (Patent Document 4) is a cellobiose impurity, and the component having a cell-killing effect on cancer cells is a component other than cellobiose. That is, (Patent Document 4) does not disclose the technical idea regarding the antitumor action of cellobiose. As shown in FIGS.
- the fact that high-purity cellobiose does not directly have a killing effect on cancer cells is that cellobiose is induced by a carcinogen as demonstrated in the above-mentioned Examples. This is consistent with suppressing the occurrence of cancer. That is, in the present invention, it is considered that cellobiose does not directly act on cells but acts on the immune system of the living body to enhance the immunity, resulting in an antitumor effect.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
(2)上記(1)に記載の抗腫瘍剤を含有する医薬品。
(3)上記(1)に記載の抗腫瘍剤を含有する食品。
本発明に係る抗腫瘍剤は、セロビオースを有効成分とすることを特徴とする。セロビオースは、2つのグルコース分子がβ1、4結合でつながった二糖であり、化学式はC12H22O11である。このようなセロビオースは、セルロース系物質をセルラーゼで分解する方法、グルコース糖の単糖類又はその誘導体を縮合もしくは糖転移させる方法、スクロースから合成する方法等により適宜製造することができる。
1.試験目的
ラットDMBA誘発乳癌モデルを用いて、セロビオースの抗腫瘍作用を検討した。
本試験は、以下の法律、基準及び指針を準用した。
・動物の愛護及び管理に関する法律〔法律第105号、昭和48年10月1日(平成23年8月30日最終改正:法律第105号)〕
・実験動物の飼養及び保管並びに苦痛の軽減に関する基準(環境省告示第88号、平成18年4月28日)
・動物の殺処分方法に関する指針〔総理府告示第40号、平成7年7月4日(平成19年11月12日一部改正:環境省告示第105号)〕
なお、本試験は、試験実施施設内動物実験委員会が規定する動物実験計画書の審議・承認を得た後に実施した。
ラットDMBA誘発乳癌モデルを用いて、セロビオースの抗腫瘍作用を検討した。具体的には、7週齢の雌性ラットを体重を指標にして群分け後、7,12-ジメチルベンゾ[a]アントラセン(DMBA)を20mg/mL/匹で強制経口投与した。そして、被験物質を4及び40mg/kg/日の2用量で、群分け日の翌日より1日1回12週間連続で強制経口投与した。
その結果、低用量及び高用量群では、ともに腫瘍の発生時期が対照群と比較して遅く、高用量群は腫瘍重量についても対照群と比較して有意ではないが、低い値を示した。このことから、被験物質であるセロビオースは、発癌性物質であるDMBAにより誘発される乳がんに対して、その発生を抑制することが示唆された。
(1)被験物質及び媒体
イ)被験物質
名称 :セロビオース
性状 :粉末
保存条件 :低温保存
取扱い上の注意 :吸湿性が高いので、使用後は密閉し、湿気に注意した。
名称 :注射用水
保存条件 :室温
製造元 :大塚製薬工場(株)
取扱い上の注意 :特になし。
名称 :カルボキシメチルセルロースナトリウム
保存条件 :室温
製造元 :関東化学(株)
取扱い上の注意 :特になし。
発癌剤として、以下の試薬を使用した。
イ)DMBA
名称 :7,12-ジメチルベンゾ[a]アントラセン
保存条件 :室温
製造元 :SIGMA
取扱い上の注意 :吸入及び皮膚への付着を避けるために、マスク、安全メガネ及び手袋を着用した。
名称 :ごま油
保存条件 :室温
製造元 :SIGMA
取扱い上の注意 :特になし。
6週齢のラット、Crl:CD(SD)(SPF)、雌性を日本チャールス・リバー(株)より2012年3月28日に52匹購入した(発注数:50匹)。
動物は入荷日に耳パンチ法により個体識別し、入荷から群分け日まで馴化した。一般状態観察を毎日行い、一般状態及び体重推移に異常が見られなかった動物を選択し使用した。各ケージには、群分け前は試験番号、性別及び個体識別番号(耳パンチ番号)を記入したカードを付し、群分け後は群及び動物番号を追記した。
馴化飼育及び実験期間を通じ、温度22±3℃、湿度50±20%、照明12時間(8:00~20:00)、換気回数13~17回/時間の環境下で、ステンレス製可動ラック(1790W×470D×1650H、mm)に設置したステンレス製金網2連ケージの1区画(255W×185D×200H、mm)に個別で収容した。飼料は、固型飼料CRF-1(オリエンタル酵母工業(株))を、ステンレス製固型飼料給餌器を用いて自由に与えた。水は、ポリサルフォン製給水器(先管ステンレス製)により、水道水を自由に与えた。
(1)群分け
検疫・馴化期間中の一般状態観察において異常が認められない動物を選択し、体重を指標として、層別連続無作為化法により下記群構成表(表1)に基づき群分けを行った。残余動物については、群分け実施日に試験群から除外し、エーテルの過剰麻酔により安楽死させ処分した。
飼育環境のモニタリングをするために、群分け後の残余動物のうち検疫・馴化期間に異常の見られなかった3匹の動物を、個体識別番号の若い順に選定して、モニタリング動物を設定した。モニタリング動物は、試験群と同一の動物室で、試験群の最終剖検日まで飼育した。
イ)発癌剤の調製
DMBAを、電子上皿天秤Sartorius Laboratory(ザルトリウス(株))を用いて必要量秤量した。秤量したDMBAは、ごま油の入ったビーカーに入れ、マイティーマグネチックスターラー(小池精密機器製作所)を用いて完全に溶解するまで攪拌した。溶解後、メスシリンダーに移して20 mg/mLの濃度になるようにメスアップした。調製時には、吸入及び皮膚への付着を避けるためにマスク、安全メガネ及び手袋を着用し、ケミカルハザード対策を行った。用時調製とした。投与後の残余発癌剤は、医療廃棄物として処理した。
群分け後のそれぞれの動物に発癌剤を投与した。すなわち、経口ゾンデ(ディスポーザブル経口ゾンデ、(有)フチガミ器械)と注射筒(ディスポーザブルシリンジ、テルモ(株))を用いて、1mL/匹の投与量で強制経口投与した。投与時には、吸入及び皮膚への付着を避けるために、マスク、安全メガネ及び手袋を着用した。
イ)被験物質投与液の調製
媒体の調製は、CMCを電子上皿天秤Sartorius Laboratory(ザルトリウス(株))を用いて必要量秤量した。秤量したCMCは、ビーカーに入れた蒸留水をマイティーマグネチックスターラー(小池精密機器製作所)を用いて撹拌しながら、少しずつ加えた。メスシリンダーに移して0.5%(W/V)にメスアップした。調製した媒体は、調製日を含めて9日間を限度に冷蔵下で保存し使用した。
群分け日の翌日から投与を開始した(1日目とした)。1日1回12週間連続で強制経口投与した。
投与の際には、経口ゾンデ(ディスポーザブル経口ゾンデ、(有)フチガミ器械)と注射筒(ディスポーザブルシリンジ、テルモ(株))を用いて、群構成表に従って5mL/kg/dayで強制経口投与した。投与液量は、投与時に最も近い日に測定した体重値から算出した。
発癌剤の投与後、一般状態観察を毎日行った。体重測定を週1回の割合で行った。
腫瘍の発生が確認される場合は、発生している腫瘍の個数を測定し、各腫瘍の推定腫瘍体積(mm3)を週1回の割合で算出した。なお、各腫瘍の推定腫瘍体積(mm3)は、腫瘍付近の剃毛を行いノギスを用いて腫瘍径(長径a及び短径b、mm)を測定後、下記式に従って算出し、各腫瘍における推定腫瘍体積の総和を求めた。
各腫瘍の推定腫瘍体積(mm3)=0.5×a×b2
投与期間終了日に糞便採取を行った。採取日の午前中に、2連ケージから繁殖ケージに個体別に動物を移した。1時間放置し、繁殖ケージに排泄された糞便を動物ごとに回収し、-80℃に設定したディープフリーザーで保存した。
投与期間終了日の翌日に解剖を行った。エーテルによる麻酔下で開腹し、腹大動脈から放血して安楽死させた。その後、各個体の腫瘍を全て摘出し、電子天秤TX323L((株)島津製作所)を用いて湿重量を測定した。湿重量測定後の腫瘍は廃棄した。
得られた数値(体重、推定腫瘍体積及び解剖時摘出腫瘍重量)は、各群で平均値及び標準誤差を算出した。
各群間の有意差は、Bartlett法により等分散性の検定を行い、等分散の場合はさらに一元配置分散分析を行い、有意である場合はTukey法により平均値の比較を行った。不等分散の場合はKruskal-WallisのH検定を行い、有意である場合はTukey法により平均順位の比較を行った。Bartlett法、一元配置分散分析及びKruskal-WallisのH検定については、有意水準を危険率5%、Tukey法については有意水準を危険率5%及び1%とした。
(1)一般状態及び体重推移
各群の体重推移を図1に示す。対照群は、試験期間を通じて増加した。低用量群と高用量群は、対照群とほぼ同様の推移を示した。各群間に有意差は認められなかった。
また、一般状態については、対照群で8日目に1匹死亡が認められた(動物番号:007)。低用量群で4日目に1匹死亡が認められた(動物番号:106)。高用量群で76日目に1匹死亡が認められた(動物番号:209)。
各群の腫瘍発生個体数推移を図2に示す。対照群は35日目に腫瘍の発生が認められた個体数は1匹であった。その後、発生個体は増加し84日目では10匹であった。低用量群は42日目まで腫瘍の発生は認められなかった。49日目に腫瘍の発生が認められた個体数は4匹であった。その後、発生個体は増加し84日目では11匹であった。高用量群は42日目まで腫瘍の発生は認められなかった。49日目に腫瘍の発生が認められた個体数は2匹であった。その後、発生個体は増加し84日目では11匹であった。
各群の推定腫瘍体積推移を図3に示す。対照群は、35日目(5週後)から腫瘍の発生が確認された。その後、新たな腫瘍発生が確認され、それぞれの腫瘍体積も増加を示した。低用量群は、49日目(7週後)から腫瘍の発生が確認された。その後、新たな腫瘍発生が確認され、それぞれの腫瘍体積は増加を示した。42日目の時点では、対照群と比較して有意に低い値であった。高用量群は、49日目(7週後)から腫瘍の発生が確認された。その後、新たな腫瘍発生が確認され、それぞれの腫瘍体積は増加を示した。42及び49日目に、対照群と比較して有意に低い値であった。
各群の腫瘍湿重量を図4に示す。低用量群は、対照群とほぼ同様の湿重量であった。高用量群は、対照群と比較して有意ではないが、低い値を示した。
低用量及び高用量群では、ともに腫瘍の発生時期が対照群と比較して遅く、高用量群は腫瘍重量についても対照群と比較して有意ではないが低い値を示した。このことから、被験物質であるセロビオースは、発癌性物質であるDMBAにより誘発される乳がんに対して、その発生を抑制することが示唆された。
セロビオースについての13C NMR、1H NMR及びIR測定を行った。得られたNMRスペクトル及び赤外吸収スペクトルを図5~7に示す。
図6と上記(特許文献4)のFIGURE 4のNMRチャートとの比較から明らかなように、セロビオース特有のピークが両チャートに確認されたが、FIGURE 4のNMRチャートにおいては、さらに別の位置にピークが確認された。この結果から、図5~7で示されているものは高純度のセロビオースであるのに対して、(特許文献4)に記載されているものはセロビオースの不純物であることが明らかとなった。
セロビオースを用いて細胞生存率に関する試験を次の方法で行った。
各種株化細胞に対する被験物質(セロビオース)の選択的殺細胞活性の有無を検討した。
(1)被験物質
名称 :セロビオース
保管方法 :冷蔵、暗所、除湿
(2)使用細胞
細胞種 :HeLa(ヒト子宮頸ガン由来細胞株)、HaCaT(ヒト由来不死化角化細胞)及びHep-G2(ヒト肝ガン由来細胞株)
(3)使用培地
培地名 :HeLa専用培地、HaCaT専用培地及びHep-G2専用培地
(4)使用試薬(XTTアッセイ用)
試薬名 :Cell Proliferation Kit(XTT)
メーカー名 :コスモ・バイオ(株)
カタログNo. :20-300-1000
(細胞の解凍・継代)
(1)HeLa、HaCaT及びHep-G2を解凍し、各種専用培地で培養した。
(2)2~3回細胞継代を行った。
(3)増殖性が回復した細胞を試験に使用した。
(1)HeLa、HaCaT及びHep-G2を96ウェルプレート2枚のそれぞれに1×104細胞/100μL/ウェルで24ウェル分播種した。
(2)24時間、CO2インキュベーター内で培養した。
(3)被験物質を0(対照)、0.001、0.01、0.1、1及び10mg/mLの6段階の濃度で添加した(N=4)。
(4)添加後、3時間CO2インキュベーターで培養した。
(5)培養後、細胞の写真撮影を行った。
(6)写真撮影後、各種細胞を培養した96ウェルプレート1枚の被験物質が含まれる培地を除去し、通常の培地に交換した。
(7)XTT reagentを50μL添加した。
(8)添加後、3時間CO2インキュベーターで培養した。
(9)450~500nmの吸光度を測定した(ref.:630~690nm)。
(1)HeLaを96ウェルプレート1枚に1×104細胞/100μL/ウェルで16ウェル分播種した。
(2)24時間、CO2インキュベーター内で培養した。
(3)デキサメタゾンを、0(対照)、10、100及び500μMの3段階の濃度で添加した(N=4)。
(4)添加後、3時間CO2インキュベーターで培養した。
(5)XTT reagentを50μL添加した。
(6)添加後、3時間CO2インキュベーターで培養した。
(7)450~500nmの吸光度を測定した(ref.:630~690nm)。
HeLa、HaCaT及びHep-G2についてのXTTアッセイの結果を図8~10に示す。図8~10から明らかなように、HeLa及びHaCaTは被験物質10mg/mLの濃度においても、生存率はコントロールと比較して、ほとんど変化は認められなかった。また、Hep-G2では被験物質の高濃度群において最大約15%の生存率の減少が認められた。また、使用キットの性能確認として、HeLaを用いて、アポトーシス誘導剤であるデキサメタゾンを使用してアッセイを行った。その結果を図11に示す。デキサメタゾン500μMにおいて約40%の生存率の低下が認められたことから、キットの性能には問題ないことが確認された。
Claims (3)
- セロビオースを有効成分とする抗腫瘍剤。
- 請求項1に記載の抗腫瘍剤を含有する医薬品。
- 請求項1に記載の抗腫瘍剤を含有する食品。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013544956A JP5841168B2 (ja) | 2012-08-24 | 2013-08-26 | 抗腫瘍剤 |
EP13821780.7A EP2889035A4 (en) | 2012-08-24 | 2013-08-26 | ANTI-TUMOR AGENT |
CN201380002486.6A CN103764152A (zh) | 2012-08-24 | 2013-08-26 | 抗肿瘤剂 |
US14/234,886 US20140221640A1 (en) | 2012-08-24 | 2013-08-26 | Antitumor agent |
US15/064,290 US20160184335A1 (en) | 2012-08-24 | 2016-03-08 | Antitumor agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JPPCT/JP2012/071414 | 2012-08-24 | ||
PCT/JP2012/071414 WO2014030250A1 (ja) | 2012-08-24 | 2012-08-24 | 抗腫瘍剤 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/234,886 A-371-Of-International US20140221640A1 (en) | 2012-08-24 | 2013-08-26 | Antitumor agent |
US15/064,290 Continuation US20160184335A1 (en) | 2012-08-24 | 2016-03-08 | Antitumor agent |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014030763A1 true WO2014030763A1 (ja) | 2014-02-27 |
Family
ID=50149583
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2012/071414 WO2014030250A1 (ja) | 2012-08-24 | 2012-08-24 | 抗腫瘍剤 |
PCT/JP2013/072686 WO2014030763A1 (ja) | 2012-08-24 | 2013-08-26 | 抗腫瘍剤 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2012/071414 WO2014030250A1 (ja) | 2012-08-24 | 2012-08-24 | 抗腫瘍剤 |
Country Status (4)
Country | Link |
---|---|
US (2) | US20140221640A1 (ja) |
EP (1) | EP2889035A4 (ja) |
CN (2) | CN106361757A (ja) |
WO (2) | WO2014030250A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5841168B2 (ja) * | 2012-08-24 | 2016-01-13 | カクイ株式会社 | 抗腫瘍剤 |
JP6155632B2 (ja) * | 2012-12-25 | 2017-07-05 | 日本製紙株式会社 | イソフラボン変換促進組成物 |
EP3247403A1 (de) * | 2015-01-22 | 2017-11-29 | Pfeifer & Langen GmbH & Co. KG | Cellobiose in zusammensetzungen zum verzehr oder zur einnahme |
CN108686220A (zh) * | 2018-07-13 | 2018-10-23 | 刘慧荣 | 一种针对甲状腺癌的抗肿瘤剂 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002179577A (ja) | 2000-12-12 | 2002-06-26 | Club Cosmetics Co Ltd | 抗腫瘍物質及び抗腫瘍剤 |
JP2005008616A (ja) * | 2003-05-29 | 2005-01-13 | Showa Sangyo Co Ltd | 免疫賦活剤 |
WO2007037249A1 (ja) * | 2005-09-27 | 2007-04-05 | Asahi Kasei Chemicals Corporation | セロオリゴ糖含有組成物 |
JP2007525483A (ja) * | 2003-10-24 | 2007-09-06 | エヌ.ブイ.・ヌートリシア | 免疫調節性オリゴ糖 |
JP2007330177A (ja) | 2006-06-16 | 2007-12-27 | Asahi Kasei Chemicals Corp | 腸内細菌賦活剤 |
JP2008208093A (ja) | 2007-02-28 | 2008-09-11 | Oji Paper Co Ltd | 抗腫瘍剤 |
WO2011110190A1 (en) | 2010-03-08 | 2011-09-15 | Romina Znoj | A cellobiose compound from herbal extracts having apoptotic activity |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1120399A (en) * | 1979-09-28 | 1982-03-23 | Universite De Sherbrooke | Pharmaceutical compositions for treatment of tumor cells |
EP1944021B1 (en) * | 2005-11-02 | 2014-05-21 | Kabushiki Kaisha Yakult Honsha | Equol level regulator |
KR20080109795A (ko) * | 2006-03-31 | 2008-12-17 | 닛뽄세이시케미카루가부시키가이샤 | 음식용 조성물 |
JP2009084215A (ja) * | 2007-09-28 | 2009-04-23 | Nippon Paper Chemicals Co Ltd | 炎症性腸疾患予防・治療剤 |
CN102068584B (zh) * | 2009-12-15 | 2015-11-25 | 四川大学华西医院 | 一种黄姜疏水性甾体皂苷提取物及其制备方法和用途 |
-
2012
- 2012-08-24 WO PCT/JP2012/071414 patent/WO2014030250A1/ja active Application Filing
-
2013
- 2013-08-26 WO PCT/JP2013/072686 patent/WO2014030763A1/ja active Application Filing
- 2013-08-26 CN CN201610647433.5A patent/CN106361757A/zh active Pending
- 2013-08-26 EP EP13821780.7A patent/EP2889035A4/en not_active Withdrawn
- 2013-08-26 US US14/234,886 patent/US20140221640A1/en not_active Abandoned
- 2013-08-26 CN CN201380002486.6A patent/CN103764152A/zh active Pending
-
2016
- 2016-03-08 US US15/064,290 patent/US20160184335A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002179577A (ja) | 2000-12-12 | 2002-06-26 | Club Cosmetics Co Ltd | 抗腫瘍物質及び抗腫瘍剤 |
JP2005008616A (ja) * | 2003-05-29 | 2005-01-13 | Showa Sangyo Co Ltd | 免疫賦活剤 |
JP2007525483A (ja) * | 2003-10-24 | 2007-09-06 | エヌ.ブイ.・ヌートリシア | 免疫調節性オリゴ糖 |
WO2007037249A1 (ja) * | 2005-09-27 | 2007-04-05 | Asahi Kasei Chemicals Corporation | セロオリゴ糖含有組成物 |
JP2007330177A (ja) | 2006-06-16 | 2007-12-27 | Asahi Kasei Chemicals Corp | 腸内細菌賦活剤 |
JP2008208093A (ja) | 2007-02-28 | 2008-09-11 | Oji Paper Co Ltd | 抗腫瘍剤 |
WO2011110190A1 (en) | 2010-03-08 | 2011-09-15 | Romina Znoj | A cellobiose compound from herbal extracts having apoptotic activity |
Non-Patent Citations (1)
Title |
---|
See also references of EP2889035A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP2889035A4 (en) | 2016-07-13 |
CN103764152A (zh) | 2014-04-30 |
EP2889035A1 (en) | 2015-07-01 |
WO2014030250A1 (ja) | 2014-02-27 |
CN106361757A (zh) | 2017-02-01 |
US20140221640A1 (en) | 2014-08-07 |
US20160184335A1 (en) | 2016-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101424125B1 (ko) | 갈색거저리 유충을 포함하는 염증성 질환 치료용 조성물 | |
WO2014030763A1 (ja) | 抗腫瘍剤 | |
WO2006033412A1 (ja) | 放射線障害軽減剤 | |
JP2009249315A (ja) | ミネラル吸収促進剤ならびに鉄欠乏性貧血改善剤または食品組成物 | |
CN103341114A (zh) | 草果油在制备治疗细菌感染性疾病的药物中的用途 | |
CN107648326B (zh) | 一种禽畜用苋黄止痢口服液的制备方法 | |
JP4831711B1 (ja) | タモギタケ抽出物を有効成分とする抗カンジダ菌剤ならびにカンジダ症予防および/または治療剤 | |
CN105340893B (zh) | 一种农用抗逆组合物及其制备方法和应用 | |
CN101317904B (zh) | 乌梅提取物在制备抗畜禽病毒药物中的用途 | |
JP5002127B2 (ja) | アカシア属樹皮由来物を含有する血糖降下組成物 | |
JP5841168B2 (ja) | 抗腫瘍剤 | |
CN106361741B (zh) | 一种用于治疗便秘的叶绿素组合物 | |
KR101870280B1 (ko) | 육계 및 육계나무의 엽병을 유효성분으로 함유하는 숙취 해소용 조성물 | |
Aminzadeh-Gohari et al. | Dietary restriction in senolysis and prevention and treatment of disease | |
JP5187935B2 (ja) | 羅漢果エキスを含有する創傷治癒促進組成物と適用方法 | |
JP2015038046A (ja) | Sirt6誘導剤 | |
WO2016072507A1 (ja) | 消化性潰瘍の予防又は治療剤,及び予防又は治療のための食品添加物,iNOS発現抑制剤及びCOX-2発現抑制剤 | |
CN115279383A (zh) | 用于治疗和预防胃肠炎症的普拉梭菌菌株cncm i-4573与pentasa®的组合 | |
JP2002104979A (ja) | ケフィアを用いた糖尿病治療剤とその製造方法、及びケフィアを用いた放射線障害防護剤、並びにケフィアを用いた健康食品 | |
JP2012153612A (ja) | マクロファージからの一酸化窒素産生亢進剤、抗腫瘍剤ならびにそれを含む医薬組成物、食品、飼料、および化粧品 | |
Ramamurthy et al. | Assessing the cytotoxic effect and antimicrobial activity of Moringa oleifera aqueous and ethanolic extract against oral pathogens extracted from periodontal and orthodontic patients | |
CN107714838A (zh) | 一种预防和治疗断奶仔猪腹泻的中药组合物及其应用 | |
JP4974475B2 (ja) | アカシア属樹皮由来物を含有する掻痒の予防及び/又は治療用組成物 | |
RU2418579C1 (ru) | Иммуностимулирующий препарат для нормализации обмена селена и коррекции стрессовых состояний для сельскохозяйственных животных | |
JP7048025B2 (ja) | 骨代謝改善用組成物及び骨代謝改善用食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2013544956 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14234886 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013821780 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13821780 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |